IDEXX Laboratories, Inc. (IDXX) SEC Filings & Earnings Calls
EquiReason read 13 IDEXX Laboratories, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — IDEXX reported strong Q2 2026 results with revenue +9.7% YoY, net income +15.1% YoY, and operating cash flow +44.8% YoY, driven by 11% growth in CAG Diagnostics recurring revenue..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 44.1B
- P/E TTM
- 39.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
4 Aug 202610-QIDEXX reported strong Q2 2026 results with revenue +9.7% YoY, net income +15.1% YoY, and operating cash flow +44.8% YoY, driven by 11% growth in CAG Diagnostics recurring revenue.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $1.22B | +10% y/y |
| Net income · Q2-2026 | $338M | +15% y/y |
| Operating cash flow · H1-2026 | $613M | +45% y/y |
| CAG Diagnostics recurring revenue · CAG · Q2-2026 | $975M | +11% y/y |
| CAG segment revenue · CAG · Q2-2026 | $1.12B | +9% y/y |
| Water segment revenue · Water · Q2-2026 | $59M | +15% y/y |
| LPD segment revenue · LPD · Q2-2026 | $35M | +11% y/y |
| Gross margin · Q2-2026 | 64.0% | |
| Diluted EPS · Q2-2026 | $4.27 | +18% y/y |
Risks flagged
Credit loss exposure
“Allowance for credit losses on accounts receivable increased to $15.0M at June 30, 2026 from $11.3M at December 31, 2025.”
Foreign exchange risk
“Foreign currency translation adjustments of ($4.5M) in Q2 2026 vs $43.0M gain in Q2 2025, indicating FX volatility.”
4 Aug 20268-K · 2.02Revenue $1.22B (+10% y/y); EPS $4.27 (+18% y/y); Gross margin 64; Guidance: Revenue guidance raised $5M at midpoint to $4,700M-$4,745M; EPS raised $0.14 to $14.69-$14.94earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $1.22B | +10% y/y |
| EPS · Q2-2026 | $4.27 | +18% y/y |
| Gross margin · Q2-2026 | 64.0% | |
| Operating margin · Q2-2026 | 35.0% | |
| CAG Diagnostics recurring revenue growth · CAG Diagnostics · Q2-2026 | 11.0% | |
| IDEXX inVue Dx installed base · Q2-2026 | 9,000 | |
| FY2026 revenue guidance · FY2026 | $4.72B |
Guidance
Revenue guidance raised $5M at midpoint to $4,700M-$4,745M; EPS raised $0.14 to $14.69-$14.94
IDEXX raised FY2026 guidance across revenue, EPS, and operating margin, reflecting strong operational performance.
Risks flagged
Foreign exchange headwind of $15M on revenue; stronger USD could pressure international results.
“Net of $15 million headwind from updated foreign exchange estimates.” · word for word
5 May 202610-QTotal revenue $1.14B (+14% y/y); Net income $278M (+15% y/y); Operating cash flow $266M (+12% y/y)open
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $1.14B | +14% y/y |
| Net income · Q1-2026 | $278M | +15% y/y |
| Operating cash flow · Q1-2026 | $266M | +12% y/y |
| Free cash flow · Q1-2026 | $234M | +13% y/y |
| CAG segment revenue · CAG · Q1-2026 | $1.05B | +15% y/y |
| IDEXX VetLab consumables revenue · CAG · Q1-2026 | $413M | +20% y/y |
| Reference laboratory diagnostic and consulting services revenue · CAG · Q1-2026 | $386M | +12% y/y |
| CAG Diagnostics capital - instruments revenue · CAG · Q1-2026 | $42M | +33% y/y |
| Water segment revenue · Water · Q1-2026 | $50M | +11% y/y |
| LPD segment revenue · LPD · Q1-2026 | $32M | +14% y/y |
Risks flagged
Credit loss exposure
“Allowance for credit losses associated with accounts receivable increased to $14.3 million from $11.3 million at year-end 2025.” · word for word
Leverage increase
“Credit facility borrowings increased to $530.0 million from $398.0 million at year-end 2025, primarily to fund share repurchases.”
5 May 20268-K · 2.02Revenue $1.14B (+14% y/y); Earnings per diluted share (EPS) $3.47 (+17% y/y); CAG Diagnostics recurring revenue growth 14; Guidance: Revenue guidance raised by ~$42M at midpoint; EPS guidance raised by $0.13 at midpointearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $1.14B | +14% y/y |
| Earnings per diluted share (EPS) · Q1-2026 | $3.47 | +17% y/y |
| CAG Diagnostics recurring revenue growth · CAG Diagnostics · Q1-2026 | 14.0% | |
| Operating margin · Q1-2026 | 31.8% |
Guidance
Revenue guidance raised by ~$42M at midpoint; EPS guidance raised by $0.13 at midpoint
Raised FY2026 revenue and EPS guidance driven by strong Q1 performance and CAG Diagnostics recurring revenue strength.
Risks flagged
Inflationary impacts and investments may pressure margins if volume growth slows.
“Gross margin expansion partially offset by inflationary impacts and investments.”
27 Mar 2026DEF 14AIDEXX filed its 2026 proxy statement (DEF 14A) for the annual shareholder meeting, including proposals for director elections, ratification of auditor, advisory vote on executive compensation, amendments to declassify the board and provideopen
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $4.30B | +10% y/y |
| Organic Revenue Growth · FY2025 | 9.6% | |
| CAG Diagnostics Recurring Revenue Organic Growth · CAG Diagnostics · FY2025 | 8.1% | |
| Operating Margin · FY2025 | 31.6% | |
| Comparable Operating Margin · FY2025 | 31.4% | |
| Earnings Per Share (Diluted) · FY2025 | $13.08 | +23% y/y |
| Comparable EPS Growth · FY2025 | 14.0% | |
| After-Tax Return on Invested Capital (ROIC) · FY2025 | 50.2% | |
| Free Cash Flow · FY2025 | $1.06B | |
| Free Cash Flow to Net Income Ratio · FY2025 | 100.0% |
Risks flagged
Macroeconomic and Geopolitical Risk
“These forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include, among other things, the adverse impact, and the duration, of macroeconomic and geopolitical events, conditions and uncer” · word for word
26 Mar 20268-K · 5.02Salary continuation $1M; Target annual bonus for two years $984,000.00; COBRA premium lump sum $50,000.00open
Figures in the filing · each found in the filing text
| Salary continuation · 2026 | $1M | |
| Target annual bonus for two years · 2026 | $984000.00 | |
| COBRA premium lump sum · 2026 | $50000.00 | |
| Transition assistance benefit · 2026 | $10000.00 |
Risks flagged
Loss of a senior strategy and commercial executive could disrupt ongoing strategic initiatives, though position elimination suggests planned restructuring.
“EVP Global Strategy and Commercial role eliminated; separation agreement includes non-disparagement and cooperation covenants.”
20 Feb 202610-KResearch and development expenses $251M (+14% y/y); R&D as % of revenue 5.8open
Figures in the filing · each found in the filing text
| Research and development expenses · FY2025 | $251M | +14% y/y |
| R&D as % of revenue · FY2025 | 5.8% |
Risks flagged
Intense Competition
“The companion animal healthcare industry is highly competitive, and we anticipate increasing competition from both existing competitors and new sector entrants.” · word for word
Customer Consolidation
“Corporate owners of veterinary hospitals and buying consortiums often seek to improve profitability by leveraging the buying power they derive from their scale to obtain favorable pricing from suppliers.” · word for word
Supply Chain Dependence
“We currently purchase many products, components, and materials from sole or single sources, such as Ortho.” · word for word
AI Regulatory Risk
“Existing and potential government regulation related to AI use may also foreclose certain areas of AI use, cause us to modify how we use AI, and increase the burden and cost of research and development and compliance in this area.” · word for word
Cybersecurity Risk
“We depend on the continuous and reliable operation and security of our information technology systems and our products and services that incorporate or rely on information technology, and any disruption or significant cybersecurity breach or other incident could adversely affect our business.” · word for word
13 Feb 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Loss of board experience, but orderly transition
“Retirement effective after 2026 Annual Meeting”
2 Feb 20268-K · 2.02Revenue $1.09B (+14% y/y); Earnings per diluted share $3.08 (+18% y/y); Revenue guidance $4.63B; Guidance: 2026 revenue guidance $4,632M-$4,720M (7.6%-9.6% growth); EPS $14.29-$14.80 (+9%-13%)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $1.09B | +14% y/y |
| Earnings per diluted share · Q4-2025 | $3.08 | +18% y/y |
| Revenue guidance · FY2026 | $4.63B | |
| EPS guidance · FY2026 | $14.29 | |
| CAG Diagnostics recurring revenue growth · Companion Animal Group · Q4-2025 | 12.0% | |
| Gross margin · Q4-2025 | 60.3% | |
| Operating margin · Q4-2025 | 28.9% | |
| Full year revenue · FY2025 | $4.30B | +10% y/y |
| Full year EPS · FY2025 | $13.08 | +23% y/y |
| CAG Diagnostics recurring revenue growth guidance · Companion Animal Group · FY2026 | 8.6% |
Guidance
2026 revenue guidance $4,632M-$4,720M (7.6%-9.6% growth); EPS $14.29-$14.80 (+9%-13%)
Strong Q4 beat and raised guidance for 2026, driven by innovation and commercial execution.
Risks flagged
Inflationary impacts on gross margin partially offset by productivity and pricing.
“Gross margin expansion helped offset inflationary impacts.”
13 Jan 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Leadership transition risk is mitigated by extended overlap and internal promotion; no disruption expected.
“Succession plan with extended transition period; internal candidate with deep company knowledge.”
3 Nov 20258-K · 2.02Revenue $1.10B (+13% y/y); Earnings per share (diluted) $3.40 (+21% y/y); Gross margin 61.8; Guidance: FY2025 revenue guidance raised by $43M to $4.27B-$4.30B, EPS raised by $0.33 to $12.81-$13.01earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $1.10B | +13% y/y |
| Earnings per share (diluted) · Q3-2025 | $3.40 | +21% y/y |
| Gross margin · Q3-2025 | 61.8% | |
| Operating margin · Q3-2025 | 32.1% | |
| CAG Diagnostics recurring revenue growth (reported) · CAG Diagnostics · Q3-2025 | 11.0% | |
| CAG Diagnostics capital instrument revenue growth · CAG Diagnostics · Q3-2025 | 74.0% | |
| Water revenue growth · Water · Q3-2025 | 8.0% | |
| LPD revenue growth · LPD · Q3-2025 | 17.0% | |
| FY2025 revenue guidance · FY2025 | $4.29B |
Guidance
FY2025 revenue guidance raised by $43M to $4.27B-$4.30B, EPS raised by $0.33 to $12.81-$13.01
Guidance raised on strong revenue growth and margin expansion.
Risks flagged
Rapid assay products revenue declined 4% due to modality shift.
“Rapid assay products revenues declined 4% as reported and 5% on an organic basis.” · word for word
3 Nov 202510-QIDEXX reported strong Q3 2025 results with revenue +13.3% YoY, EPS +21.4% YoY, and operating cash flow +23.9% YoY.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $1.11B | +13% y/y |
| Total revenue · 9M-2025 | $3.21B | +9% y/y |
| Net income · Q3-2025 | $275M | +18% y/y |
| Net income · 9M-2025 | $811M | +21% y/y |
| Diluted EPS · Q3-2025 | $3.40 | +21% y/y |
| Diluted EPS · 9M-2025 | $9.99 | +24% y/y |
| Gross margin · Q3-2025 | 61.8% | |
| Operating margin · Q3-2025 | 32.1% | |
| Operating cash flow · 9M-2025 | $826M | +24% y/y |
| Free cash flow · 9M-2025 | $731M |
Risks flagged
Customer concentration risk
“No explicit customer concentration risk mentioned in the filing.”
Foreign exchange risk
“The company uses derivatives to hedge foreign exchange exposure, indicating material international operations.”
IDEXX Laboratories, Inc. — questions
- What did IDEXX Laboratories, Inc. file recently?
- 13 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — IDEXX reported strong Q2 2026 results with revenue +9.7% YoY, net income +15.1% YoY, and operating cash flow +44.8% YoY, driven by 11% growth in CAG Diagnostics recurring revenue.
Every figure on this page comes from IDEXX Laboratories, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.